About SHIZAM
Purpose and Editorial Scope
SHIZAM is an independent reference platform focused on structured, evidence-based documentation of supplement ingredients, medical ingredients, and health conditions. We organize complex clinical, scientific, and regulatory information into neutral, traceable reference articles.
The platform is structured for human readers and machine retrieval through consistent article architecture, source-linked claims, and explicit evidence boundaries.
SHIZAM does not publish promotional product claims or lifestyle-oriented wellness commentary. Its editorial focus is evidence documentation, source traceability, and research-context interpretation.
Our editorial role is to define the boundaries of available human evidence: what has been studied, under what conditions, at what exposure level, and where evidence remains limited, indirect, formulation-specific, or unresolved.
Notice: All SHIZAM content is provided for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
The SHIZAM Knowledge Libraries
SHIZAM is organized around two primary reference encyclopedias: the Supplement & Medical Ingredients Encyclopedia and the Medical & Health Conditions Encyclopedia. Together, these libraries are designed to distinguish documented human evidence from limited findings, formulation-specific results, traditional-use context, mechanistic hypotheses, and unresolved research questions.
1. Supplement & Medical Ingredients Encyclopedia
The Supplement & Medical Ingredients Encyclopedia provides structured reference articles on dietary supplement ingredients, nutrients, botanical extracts, pharmaceutical compounds, OTC ingredients, topical ingredients, excipients, and other medically relevant substances.
Ingredient entries are centered on human research findings rather than marketing claims. Each article is designed to clarify what has been studied, at what exposure level, in which population or use context, and with what level of evidence.
Core elements include:
Ingredient Identity: Classification of the substance, including botanical, nutritional, pharmaceutical, topical, or other medically relevant identity where applicable.
Human Research Findings by Use Context: Review of studied use cases, organized by relevant outcome areas rather than broad unsupported benefit claims.
Dosage & Exposure Context: Analysis of study exposures, including dose-specific findings, milligram ranges, drug-extract ratios, preparation type, route of use, and whether the evidence applies to powder, extract, liquid, topical, lozenge, capsule, or other delivery formats.
Formulation and Delivery Differences: Distinction between preparation types when research cannot be generalized across formats, such as powder versus extract, oral versus topical, or systemic versus local-use preparations.
Pharmacokinetic and Absorption Context: Review of available human data on absorption, Tmax, half-life, delivery route, and related exposure characteristics when such data exist. Evidence gaps are stated when human pharmacokinetic data are limited or unavailable.
Evidence Strength and Limitations: Classification of evidence maturity, including whether findings are supported by controlled human trials, observational studies, traditional-use assessments, regulatory reviews, or early-stage evidence.
2. Medical & Health Conditions Encyclopedia
The Medical & Health Conditions Encyclopedia provides structured reference articles on diseases, disorders, symptoms, body-system conditions, and clinical topics. These articles are designed to explain the condition itself while also mapping the intervention landscape around it.
Condition entries are not limited to conventional medical treatment summaries. They are structured to distinguish standard care, prescription therapies, procedures, dietary approaches, supplemental interventions, topical or local-use interventions where relevant, lifestyle factors, and areas where evidence remains weak or unresolved.
Core elements include:
Clinical Definition and Classification: Explanation of what the condition is, how it is classified, and how it differs from related or commonly confused conditions.
Causes, Risk Factors, and Mechanisms: Review of known or proposed biological drivers, risk factors, pathophysiology, and disease mechanisms.
Symptoms, Patterns, and Diagnostic Context: Description of common symptom patterns, differential clues, and the clinical context in which diagnosis is usually evaluated.
Standard Medical Care and Therapies: Structured summary of guideline-discussed care categories, including prescription therapies, procedures, technologies, monitoring approaches, and safety considerations where applicable.
Supplemental, Topical, Dietary, and Lifestyle Interventions: Review of human evidence for non-prescription intervention categories, including supplements, dietary approaches, topical or local-use interventions, lifestyle factors, and complementary systems when relevant evidence exists.
Evidence Gap Disclosure: Identification of areas where research is limited, mixed, negative, indirect, formulation-specific, or not yet sufficient to support broad claims.
Editorial Methodology: The Source-First Protocol
To support reliability for professional readers, general users, and machine retrieval systems, SHIZAM applies a Source-First Verification Protocol built on three principles:
Audit-Level Traceability: Every factual claim is tied to an inline citation wherever possible. SHIZAM prioritizes primary human research, systematic reviews, meta-analyses, clinical guidelines, and institutional authorities such as FDA, NIH, EMA, and EFSA.
Claim Narrowing: Findings are not generalized beyond the source. If evidence is limited to a specific population, dose, formulation, route of use, clinical context, or study design, the article reflects that limitation.
Structured Evidence Classification: SHIZAM uses evidence-confidence categories such as Strong, Moderate, Limited-Mixed, and Emerging to reduce the risk of treating early-stage, indirect, or formulation-specific evidence as established clinical proof.
The SHIZAM Editorial Team
All content published on the platform is produced and maintained by the SHIZAM Editorial Team. The team operates under an editorial framework designed to ensure that each article meets internal standards for source quality, evidence traceability, research-context accuracy, and neutrality.
The Editorial Team is responsible for source verification, evidence classification, article-structure consistency, and the removal of promotional framing or consumer-health hype. The objective is to maintain a disciplined, objective tone while making complex research easier to navigate.
Leadership and Oversight
Founder: Statement of Qualifications
Shizuma Yokozawa
Education: MBA, University of California, Berkeley, December 2000
Licensure: Certified Public Accountant, licensed by the California Board of Accountancy, License #79601
Professional Experience: Background in consulting and financial institutions, including work with Deloitte, Ernst & Young, and Merrill Lynch
This background in structured analysis, regulatory environments, and large-scale information systems informs the structural discipline of the SHIZAM platform. The objective is to apply the precision and traceability associated with audit, compliance, and financial analysis to the organization of medical, ingredient, and health-condition information.
Ownership and Commercial Disclosure
The SHIZAM ® brand has been active in the United States dietary supplement market since 2021, with products sold on Amazon USA.
The educational publishing activities of this website are managed by SHIZAM Limited, a Canadian corporation. To preserve editorial neutrality, SHIZAM maintains functional separation between commercial product operations and educational publishing.
Reference content is produced independently of product sales, product marketing, and promotional objectives. Editorial decisions are based on source quality, evidence relevance, article-scope requirements, and the need to distinguish documented evidence from unsupported or overgeneralized claims.
SHIZAM Limited holds the exclusive right to use the SHIZAM® trademark for these activities.
Contact Information
SHIZAM Limited
3465 Platinum Dr, Unit 238-1004
Mississauga, Ontario
L5M 2S1
Canada
Email: info@shizam.ca
Web: www.shizam.ca